S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.01%) $0.927
USD/NOK
(0.19%) $10.86
USD/GBP
(0.07%) $0.793
USD/RUB
(-0.32%) $92.28

Realtime updates for DBV Technologies S.A. [DBVT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

-1.02% $ 0.749

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...

Stats
Today's Volume 14 547.00
Average Volume 52 611.00
Market Cap 144.14M
EPS $0 ( 2024-03-07 )
Next earnings date ( $-0.220 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.970
ATR14 $0.00800 (1.07%)
Insider Trading
Date Person Action Amount type
2024-03-08 Tasse Daniel Buy 17 094 Ordinary Shares
2024-02-06 Ndu Adora Buy 1 825 Ordinary Shares
2023-11-22 Mohideen Pharis Sell 2 245 Ordinary Shares
2023-11-20 Boucinha Virginie Buy 113 000 Employee Stock Option (right to buy)
2023-11-20 Boucinha Virginie Buy 19 000 Ordinary Shares
INSIDER POWER
99.88
Last 57 transactions
Buy: 29 162 445 | Sell: 1 080 406

DBV Technologies S.A. Correlation

10 Most Positive Correlations
PLPC0.902
GPOR0.891
MCAA0.89
ENTF0.887
MLAI0.886
PPYA0.884
AHRN0.883
FRSG0.882
ACQR0.88
FTAA0.88
10 Most Negative Correlations
INCY-0.916
SRTS-0.904
FARO-0.897
BXRX-0.896
NWL-0.895
CDXS-0.892
NURO-0.888
AYTU-0.888
RCKY-0.886
SBAC-0.88

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DBV Technologies S.A. Financials

Annual 2023
Revenue: $0
Gross Profit: $4.50M (0.00 %)
EPS: $-0.380
Q4 2023
Revenue: $0
Gross Profit: $13.57M (0.00 %)
EPS: $-0.0581
Q3 2023
Revenue: $2.40M
Gross Profit: $1.94M (81.02 %)
EPS: $-0.170
Q2 2023
Revenue: $2.29M
Gross Profit: $-2.69M (-117.57 %)
EPS: $-0.260

Financial Reports:

No articles found.

DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators